Nykode Therapeutics ASA (NYKD)

Currency in NOK
3.16
-0.07(-2.17%)
Closed·
High dividend Yield
NYKD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.163.26
52 wk Range
1.444.10
Key Statistics
Prev. Close
3.16
Open
3.26
Day's Range
3.16-3.26
52 wk Range
1.44-4.1
Volume
390.29K
Average Volume (3m)
1.23M
1-Year Change
27.94%
Book Value / Share
2.83
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NYKD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Nykode Therapeutics ASA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Nykode Therapeutics ASA Earnings Call Summary for Q3/2025

  • Nykode Therapeutics reduced Q3 2025 net loss to $3.7M (from $9.7M in Q3 2024) while cutting operating expenses to $6.4M (from $15.6M), despite revenue declining to $118K.
  • The company maintains a strong $64M cash position with runway extended to 2028-2029, plus potential $32.5M from a pending tax case.
  • Nykode plans a randomized Phase 2 trial for lead asset AviSuva targeting HPV16-driven cancers, with interim data expected by H1 2026.
  • VB10.NEO, the company's individualized neoantigen therapy, received a U.S. patent for its NeoSelect platform, positioning it as 'the most attractive, unencumbered INT asset.'
Last Updated: 24/11/2025, 14:56
Read Full Transcript

Earnings

Latest Release
24/11/2025
EPS / Forecast
-0.01 / -0.23
Revenue / Forecast
118K / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.04%
Dividend Yield
30.96%
Industry Median 25.86%
Annualised payout
1.00
Paid annually
5-Years Growth
-
Growth Streak

Compare NYKD to Peers and Sector

Metrics to compare
NYKD
Peers
Sector
Relationship
P/E Ratio
−9.1x−1.1x−0.5x
PEG Ratio
−0.140.000.00
Price/Book
1.2x0.8x2.6x
Price / LTM Sales
245.7x1.7x3.3x
Upside (Analyst Target)
169.0%46.0%47.1%
Fair Value Upside
Unlock6.0%6.2%Unlock

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
27.01M8.27%87.11M
Other Institutional Investors
193.96M59.40%625.53M
Public Companies & Retail Investors
105.57M32.33%340.47M
Total
326.55M100.00%1.05B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
SMALLCAP World Fund, Inc.5.22%17,038,21954,948
Danske Invest Norge Vekst0.87%2,825,4989,112

People Also Watch

2.035
SGFI
-0.73%
56.00
SMOP
+6.87%
1.14
CYB
+0.88%
258.00
VEND
+1.26%
1.69
NORSE
-1.16%

FAQ

What Is the Nykode Therapeutics (Oslo: NYKD) Share Price Today?

The Nykode Therapeutics stock price today is 3.16 NOK.

What Stock Exchange Does Nykode Therapeutics (NYKD) Trade On?

Nykode Therapeutics is listed and trades on the Oslo Stock Exchange.

What Is the Ticker (Stock Symbol) for Nykode Therapeutics?

The stock symbol (also called a 'ticker') for Nykode Therapeutics is "NYKD."

Does Nykode Therapeutics Pay Dividends? What’s The Current NYKD Dividend Yield?

Yes, NYKD Pays Dividends to its Shareholders. The current Nykode Therapeutics dividend yield is 30.96%.

What Is the Current Nykode Therapeutics Market Capitalisation?

As of today, Nykode Therapeutics (Oslo: NYKD) market cap is 1.03B NOK.

What Is Nykode Therapeutics's (NYKD) Earnings Per Share (TTM)?

The Nykode Therapeutics EPS is currently -0.04 (Trailing Twelve Months).

Is NYKD a Buy or Sell From a Technical Analyst Perspective?

Based on today's Nykode Therapeutics moving averages and other technical indicators, the daily buy/sell signal for NYKD stock is Neutral.

How Many Times Has Nykode Therapeutics Stock Split?

Nykode Therapeutics has split 1 times. (See the NYKD stock split history page for full effective split date and price information.)

How Many Employees Does Nykode Therapeutics Have?

Nykode Therapeutics has 59 employees, based on their latest Companies House report.

What is the current trading status of Nykode Therapeutics (Oslo: NYKD)?

As of 05/05/2026, Nykode Therapeutics (NYKD) is trading at a share price of 3.16 NOK, with a previous close of 3.16 NOK. The stock has fluctuated within a day range of 3.16 NOK to 3.26 NOK, while its 52-week range spans from 1.44 NOK to 4.10 NOK.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.